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a  b  s  t  r  a  c  t
In  the event  of  a highly  pathogenic  inﬂuenza  pandemic,  the Indian  subcontinent  would  need  1.2  billion
doses  of  vaccine  to immunize  its  entire  population,  double  if  two  doses  were  required  to  assure  immunity.
Serum  Institute  of  India  Limited  (SII) thus  became  one  of  six  initial  grantees  of  the World  Health  Orga-
nization  (WHO)  technology  transfer  initiative  to  create  capacity  in  developing  countries  to  manufacture
H5N1  pandemic  inﬂuenza  vaccine.  At  the  outbreak  of  the  A(H1N1)  2009  inﬂuenza  pandemic,  experience
gained  from  the  H5N1  project  was  used  to develop  a live  attenuated  inﬂuenza  vaccine  (LAIV),  since  this
was  the  only  option  for  the  level  of  surge  capacity  required  for a large-scale  immunization  campaign  in
India.  SII  took  <12  months  to develop  and market  its  LAIV  intranasal  vaccine  from  receipt  of  the  seed  strain
from  WHO.  As  of  November  2010,  over  2.5  million  persons  have  been  vaccinated  with  Nasovac® with no
serious  adverse  reactions  or vaccine  failure  after  3  months’  post-marketing  surveillance.  The  product  has
been  submitted  for prequaliﬁcation  by  WHO  for  purchase  by  United  Nations  agencies.  In  parallel,  SII  also
developed  an  inactivated  inﬂuenza  vaccine,  and  is  currently  looking  to  ensure  the  sustainability  of  its
inﬂuenza  vaccine  manufacturing  capacity.. Introduction
The Serum Institute of India (SII) is the world’s ﬁfth largest pro-
ucer of vaccines, with an installed capacity of over 1 billion doses.
II’s core competence in mass production of cell-culture derived
roducts makes it a major supplier of measles, mumps and rubella,
s well as diphtheria, pertussis and tetanus vaccines through the
nited Nations Children’s Fund. Given this experience and capac-
ty, SII was selected in 2006 to participate in the World Health
rganization (WHO) technology transfer initiative to strengthen
he capacity of developing countries to produce pandemic inﬂuenza
accine [1].
Countries such as India, with very large populations but no
emand for seasonal inﬂuenza vaccine, face additional techno-
ogical and ﬁnancial challenges in ensuring an adequate supply
f inﬂuenza vaccine. Although inactivated inﬂuenza vaccines (IIV)
re generally preferred for high-risk populations such as immuno-
ompromised individuals or pregnant women, the sheer number
f doses required during a pandemic to immunize over a billion
eople means that among currently licensed vaccines only live
ttenuated inﬂuenza vaccines (LAIV) could meet the challenge of
rotecting the whole Indian population. In addition to the less com-
lex downstream manufacturing process and higher yields, the
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intranasal route of administration of LAIV imitates natural infection
and presents a lower risk to the recipient compared to the injectable
administration of IIV, making it the most appropriate candidate for
mass immunization during a pandemic.
With these considerations, SII initiated the development of IIV
and also approached WHO  to obtain a sub-licence for the Russian
LAIV technology. We  present here our activities, as one of the WHO
grantees, to develop, manufacture and license both IIV and LAIV for
use in the event of an inﬂuenza pandemic.
2. Experimental studies with inactivated inﬂuenza vaccine
Our  initial objective was to gain experience and generate tech-
nical and preclinical experimental data on inﬂuenza vaccines in
order to decide on the best options for large-scale vaccine man-
ufacture. Most inﬂuenza vaccines are produced in embryonated
eggs. However, due to our extensive experience with production
of cell-culture derived vaccines, we started by exploring the devel-
opment of cell-based IIV to compare yields with those of egg-based
vaccines.
We undertook extensive work between June 2007 and June
2009 on upstream and downstream processing of egg- and tissue
culture-based IIV. A developmental and an analytical laboratory
Open access under CC BY-NC-ND license.were set up to establish protocols for vaccine production and
analytical testing, respectively. A/PR/8/34 (H1N1) prototype strain
and seasonal inﬂuenza vaccine strains A/Solomon Islands/3/2006
(H1N1), A/Wisconsin/67/2005(H3N2) and B/Malaysia/2506/2004
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Fig. 1. Comparative immune response to H5N1-NIBRG-14 whole virus and subunit
vaccine. HAI titres of adult Swiss albino mice, inoculated with two doses of 1.0 ml
vaccine three weeks apart through intraperitoneal route containing 15 g, 7.5 g,






































maximize the coverage area and reduce the potential of pulmonaryluminium  phosphate or aluminium hydroxide.
ere used to establish virus growth and puriﬁcation methods, com-
are yields in eggs and tissue culture, generate trivalent seasonal
nﬂuenza vaccine and carry out immunogenicity studies. The vac-
ine prepared using seasonal inﬂuenza strains induced an immune
esponse in mice comparable to that in commercially available vac-
ine using the same strains.
The  H5N1 NIBRG-14 strain was used to generate prototype
hole and subunit pandemic vaccine and immunogenicity stud-
es were conducted with and without adjuvants. The H5N1 whole
irion inactivated vaccine induced considerable immune response
sing aluminium adjuvant (Fig. 1). Adequate exposure and suc-
essful handling of the NIBRG-14 strain along with promising
mmunogenicity data in mice provided conﬁdence to advance
he project to clinical development and large-scale manufacture
f a H5N1 pandemic inﬂuenza vaccine at the beginning of 2009
2].
The sudden outbreak of novel H1N1 pandemic inﬂuenza virus in
ay  2009 shifted our focus away from our comparative studies to
evelop a vaccine against the novel pandemic strain in the quickest
ossible time. We  adopted the egg-based system because our stud-
es indicated that egg-based technology showed slightly superior
ields and was easier to retroﬁt into our existing production facil-
ty. Now that the H1N1 pandemic is under control, we will resume
ur studies to compare yields from egg- and cell-based technolo-
ies, but we will continue to use eggs for the manufacture of IIV as
ell as LAIV for the foreseeable future.
. H1N1 pandemic vaccine development
In May  2009, SII signed an agreement with WHO  to secure a
ub-licence for the development, manufacture and sale of a LAIV
sing the backbone of attenuated strain A/Leningrad/134/17/57
rom the Institute of Experimental Medicine (IEM), Russian Federa-
ion. This was fortuitous as it enabled us to shift the focus of vaccine
anufacturing from IIV to LAIV in view of the certainty of higher
ield of vaccine doses per egg. The development of IIV was main-
ained given the lack of data in administering LAIV to pregnant and
actating women, seriously immunocompromised recipients and
ecipients with known respiratory–pulmonary related ailments.
his made it necessary to ensure that stocks of IIV were also avail-
ble.S (2011) A16– A21 A17
3.1. Live attenuated inﬂuenza vaccine
The experience gained in growing and testing different inﬂuenza
strains proved useful in designing the manufacturing process of
LAIV. However, two  main issues had to be tackled within the limited
time available. The ﬁrst challenge was to ensure stability of the vac-
cine, and the second was to develop a delivery system that ensured
the use of the vaccine through intranasal route and not through the
injectable route due to inadequate training of health-care workers.
Once these challenges were overcome, proving clinical safety and
immunogenicity was  the ﬁnal step. Scientiﬁc groups subdivided
into independent virological, analytical, formulation and intranasal
delivery device development, and clinical activities were put into
action with clearly deﬁned goals.
3.2. The ﬁrst challenge: stability of the vaccine
Today, LAIV is marketed in the United States of America (USA)
as a liquid and in the Russian Federation as a freeze-dried product.
Since the liquid version did not meet SII’s shelf life (9 months stored
at 2–8 ◦C) or cold chain (compatible with −20 ◦C) requirements for
a pandemic vaccine, we  opted for the freeze-dried route. SII has a
lyophilization capacity of 30 million doses per year, which can be
increased to 40 million doses in the existing plant in an emergency
situation. The need for the process to be compatible with exist-
ing equipment was a prerequisite for rapid scale-up of operational
capacity to meet the pandemic requirement.
The freeze-drying cycle development activity involves the cre-
ation and study of multiple formulations and narrowing these
down to the most suitable. To reduce time, we adopted a novel
approach of ‘plugging’ the attenuated inﬂuenza virus into a for-
mulation containing excipients proven to be safe and effective in
stabilizing an established (measles) attenuated virus vaccine. In
addition to accelerating the development process, this allowed the
seamless adaptation of personnel and equipment to the manufac-
turing process, and use of the existing supply chain and safety data
for the materials. We  therefore developed a LAIV formulation, the
physicochemical properties of which were known. Estimates for
methods and temperatures of ﬁltration, expected losses in pro-
cessing, procedures for setting titres and use of a diluting medium
were based on experience with the measles vaccine. Results of sub-
sequent studies on this ‘plug in’ approach matched scientiﬁcally
predicted expectations.
Being  a pandemic vaccine, there was a need for it to be available
in multi-dose vials for mass campaigns as well as in single doses
for the commercial market.
3.3. The second challenge: the intranasal delivery system
The  vaccine was to be reconstituted with water and adminis-
tered using a system that ensures accurate measurement of dose,
maximum reusable parts and for multi-dose vials, no shared con-
tact of the device among recipients. However, certain hurdles were
encountered such as producing water for inhalation for the single-
dose diluent as the interaction of water for inhalation in such small
volumes with type 1 glass vials resulted in conductivity shifts.
While it is possible to overcome this issue with more expensive
type 1 vials treated with ammonium sulphate, regulatory agencies
need to review if this increase in cost is justiﬁed, as conductivity is
not as relevant a parameter for intranasal administration as it is for
parenteral administration.
An  intranasal spray, rather than drops, was  developed in order toentrainment in recipients in the upright position. The development
of the device presented major challenges since it had to be inex-
pensive and have a dead volume <100 L (a loss of vaccine easily









































NFig. 2. Intranasal spray device for ad
ompensated by increasing the titre). Existing snap-on metered
ose sprays did not ﬁt SII’s 13 mm  vials and would not guaran-
ee that a consistent dose could be safely administered to multiple
ecipients. Therefore, a spray device ﬁtted to the tip of a syringe
as employed (Fig. 2). The syringe measured the dose accurately,
nd the spray device, in conjunction with the syringe, generated a
pray that maximized coverage and ensured sufﬁcient positive dis-
lacement. This eliminated the need for the recipient to lie down
uring administration.
Regarding packaging, there was a concern that vaccinators
ight mistake the vaccine as an injection if a needle is pro-
ided, especially since training in the ﬁeld is not always optimum.
he package was  made needle free by developing a “needle-free
ransfer device” that cannot be used to inject the vaccine acciden-
ally. This device is attached to a syringe to draw water from the
ial, add it to the vaccine container and to withdraw the recon-
tituted vaccine. Similarly, the diluent was called “sterile water
or inhalation” (SWFInh) instead of “water for injection” to avoid
rrors. Sterile water for inhalation is covered in the US pharma-
opoeia.
.4. Pandemic vaccine manufacture and clinical studies
A/17/California/2009/38 LAIV reassortant strain generated
hrough reassortment of the A/Leningrad/134/17/57 master donor
ttenuated strain (IEM, Russian Federation) with H1N1 pandemic
/California/07/2009 was received in August 2009. Seed lots were
repared and characterized and a trial lot prepared to optimize pro-
esses including inoculation, harvesting clariﬁcation, puriﬁcation
nd concentration. The same lot was used to assess the formula-
ion and freeze-drying procedures, as well as to validate quality
ontrol tests.
A  second lot was prepared for toxicity studies in mice and rats
n October 2009. These studies revealed no toxic effects at doses
igher than the intended human dose. The vaccine was  tested in
ice challenge studies (National Institute of Virology, Pune, India)
nd was found to induce protective immunity against the wild
ype strain. Ferret challenge studies were conducted with a sin-
le dose of LAIV with signiﬁcant induction of haemagglutination
nhibition (HAI) and microneutralization (MN) antibodies and com-
lete protection against virus challenge (Fig. 3 and Table 1). This
tudy was conducted in collaboration with WHO  at Viroclinic, The
etherlands. A third lot was prepared and released for clinical
rial purposes by the SII quality control laboratory and the Indian
ational Control Authority (NCA) in January 2010.tration of H1N1 pandemic vaccine.
A Phase I, double-blind randomized study in 50 healthy adults
aged 18–49 years compared a placebo and a single dose of the study
vaccine [107 of the 50% egg infectious dose (EID50)] to assess safety
over 42 days (CTRI/2010/091/000008). No serious adverse events
(SAEs) or unsolicited events were reported. All solicited reactions
were mild in intensity and all were resolved without sequelae
within 2–3 days.
The  Phase II/III double-blind randomized trial involved 330 indi-
viduals (110 adults, 110 elderly and 110 adolescents and children
≥3 years) at ﬁve sites in India (CTRI/2010/091/000092). Subjects
received either a placebo or 107 EID50 dose of the study vaccine. The
vaccine was found safe in all age groups. No SAEs were reported and
none of the unsolicited events in either group was causally related
to the study products. The solicited reactions were similar in both
groups, all of which were mild and all resolved without sequelae.
Although  LAIV has been proved to be highly efﬁcacious in
preventing inﬂuenza virus infection, the serological correlates of
protection are not well established. From studies characterizing
the immune response following intranasal administration of LAIVs,
cell-mediated immunity (CMI) is considered to have a role in pro-
tection in adults and children that cannot be entirely explained
by mucosal or serum antibody responses. So far, the role of CMI in
protection against clinical inﬂuenza has not been established in the
ﬁeld, due to the technical difﬁculties of using these complex assays.
WHO recommended that an appropriate approach to evaluate the
immunogenicity of LAIVs in clinical trials would be to show signif-
icant uptake (e.g., that a majority of vaccinees respond), measured
by combining results from a panel of tests.
In our study, immunogenicity was  assessed on Day 0 and 21 by
HAI, MN,  and IgG from serum samples. An in-house IgA detection
assay from nasal wash/swab samples was  developed, validated and
used to test mucosal IgA response. The immune response induced
by the vaccine was  in line with published studies on LAIV [3–5].
The  above studies were conducted in accordance with the
International Conference on Harmonization-Good Clinical Practice
(ICH-GCP) guidelines; the Declaration of Helsinki (Seoul 2008);
Guidelines for Clinical Trials on Pharmaceutical Products in India
– GCP Guidelines issued by the Central Drugs Standard Control
Organization (CDSCO), 2001; Requirements and Guidelines for Per-
mission to Import and/or Manufacture of New Drugs for Sale or to
undertake Clinical Trials (Schedule Y, 2005); and Ethical Guidelines
for Biomedical Research on Human Subjects issued by the Indian
Council of Medical Research (ICMR), 2006.
Once the production process was  optimized for bulk LAIV vac-
cine lots, process validation studies were completed on three
R. Dhere et al. / Vaccine 29S (2011) A16– A21 A19
Fig. 3. Protective efﬁcacy studies of pandemic LAIV in ferrets. Lungs from ferrets challenged with wild type H1N1 were examined macroscopically. (A) Severely affected dark
hyperaemic and consolidated lung from placebo-treated control group. (B) Lungs from a vaccinated animal without discernible lesions. Normal aerated lung tissue is bright
pink  in colour.
Table  1
Immunogenicity of LAIV A/17/CALIFORNIA/2009/38 (H1N1) in ferrets after a single-dose immunization.
Average haemagglutinin titre (6 ferrets)
Haemagglutination inhibition assay Serum Day 0 Serum Day 20 Serum Day 20




































(Negative  control 5 
SII  clinical trial grade PLAIV 5 
ource: ViroClinics, The Netherlands.
onsecutive lots for licensing. The results of these studies met  all
ritical process parameters for the manufacturing process. Follow-
ng review by the Drug Controller General of India (DCG(I)) and the
CA, the ﬁnal licence was issued on 3 July 2010. The vaccine was
aunched in India on 14 July 2010 under the brand name Nasovac®
nd as at November 2010, more than 2.5 million doses have been
istributed.
.5. Inactivated inﬂuenza vaccine
In order to be able to provide vaccine for pregnant and lactating
omen, seriously immunocompromised recipients and recipi-
nts with known respiratory–pulmonary related ailments, the IIV
evelopment programme was undertaken in parallel to the LAIV
rogramme.
A seed lot was prepared using the NYMC X-179A vaccine strain
similar to the A/California/07/2009 (H1N1) strain) obtained from
he National Institute for Biological Standards and Control (NIBSC),
nited Kingdom in July 2009. A trial lot of inactivated H1N1 pan-
emic vaccine was prepared based on the knowledge acquired
uring the development of the H5N1 candidate vaccine. This trial
ot adjuvanted with aluminium hydroxide gel was ﬁlled in single
ose vials and used for in-house immunogenicity testing in mice.
he data from these tests were very encouraging as two  doses
iven 21 days apart at a concentration as low as 3.75 g per dose
roduced ≥1:40 haemagglutination inhibition (HAI) titres in all
mmunized mice (Fig. 4).
A second lot was ﬁlled, quality tested and released, and used for
oxicology studies: two single-dose and two repeated-dose studies
n mice and rats were successfully completed by an external accred-
ted laboratory. Upon approval from the DCG(I), an Independent
eview Board and the Institutional Ethics Committee for the Phase I
rial, a production scale IIV bulk lot was prepared for clinical studies
n a renovated and Good Manufacturing Practice (GMP)-compliant
acility.The Phase I, double-blind, randomized study in 50 healthy
dults aged 18–49 years (CTRI/2010/091/000082) compared the
afety of two Al(OH)3 adjuvanted whole virion formulations
10 g and 15 g haemagglutinin (HA) per dose). SatisfactoryFig. 4. Inactivated H1N1 inﬂuenza vaccine immunogenicity studies in mice.
42-day follow-up data led to authorization for the Phase II/III
double-blind, randomized study, carried out in 330 individuals
(110 adults, 110 elderly and 110 adolescents and children ≥3
years) at ﬁve sites in India (CTRI/2010/091/000093). Following
single dose of either 10 g or 15 g HA of the study vaccine
given intramuscularly at 21 days apart, safety and immunogenic-
ity were assessed and the vaccine found safe in all age groups.
After 42 days of follow-up, no SAEs were reported and none of
the few unsolicited events detected in each group was causally
related to the study products. All solicited reactions reported in
the groups were similar, mild in intensity and resolved with-
out sequelae. Immunogenicity was assessed on Day 0 and 21
by HAI assay. The vaccine-induced immune responses of both
formulations were in line with published studies [6–8]. Sero-
conversion and seroprotection (HI titres ≥1:40) rates met  the
requirements of the European Medicines Agency (EMEA) and the
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The DCG(I) granted the licence to market the 15 g adjuvanted
accine on 6 August 2010. As soon as six months of stability data
re available, the 10 g formulation will be registered and launched
nder the brand name Enzavac® in India.
. Regulatory support
All  the clinical studies were approved by the DCG(I), the Inde-
endent Review Board and the Institutional Ethics Committee.
dditionally, all data were periodically reviewed and approved by
n independent Data Safety Monitoring Board. Among other con-
rols, an on-site regulatory audit for the manufacturing processes
nd quality control testing was carried out by an inspection team
rom WHO, the CDSCO/DCG(I), and local FDA in April 2010.
During  the entire clinical development and licensing of the IIV
nd LAIV, SII was actively supported by the government agencies
ince the need for a pandemic vaccine in India was clear. As a result,
hey approved importation of the H1N1 vaccine strain, clinical trial
rotocols and ﬁnally licensure on a fast-track basis.
In  parallel, SII proactively apprised these agencies of develop-
ents at each stage of the project. For instance, while requirements
or the production and use of IIV are long established, the WHO
uidelines for the manufacture and evaluation of LAIV were being
pdated. Policy-makers and the scientiﬁc community were also
pprehensive over issues such as potential reversion of attenua-
ion to virulent phenotype, emergence of more pathogenic viruses
rom reassortant between vaccine strain and wild type strain, and
imited safety data. Extensive brainstorming activities took place
ith these groups under the auspices of the ICMR and the Ministry
f Health and Family Welfare to clarify any uncertainties. WHO’s
osition on the use of LAIV during an inﬂuenza pandemic, and data
n its use for routine immunization in the Russian Federation for
he last 30 years and in the USA since 2003 were also presented. This
pproach was invaluable in developing an objective understanding
f the safety and efﬁcacy of LAIV, and aided in obtaining marketing
uthorization.
. Post-marketing surveillance
Exhaustive  post-marketing surveillance in a large population
as been completed and has shown the vaccine to be safe. No
AE caused by Nasovac®, or vaccine failure, have been reported
fter widespread use. Periodic Safety Update Reports were sub-
itted every two weeks for the ﬁrst 3 months and these will
ontinue to be submitted on a monthly basis for a further year.
he same post-marketing surveillance activities will be followed
or IIV (Enzavac®).
.  Discussion
SII is the only private manufacturer among the initial six
rantees of the WHO  inﬂuenza technology transfer project. Impor-
ant advantages of this have been our ﬂexibility in making decisions
oth on ﬁnancial and technical issues, which is critical in handling
n emergency situation. At the onset of the H1N1 outbreak, for
xample, we immediately converted a renovated measles vaccine
roduction block for inﬂuenza vaccine and dedicated a complete
acility to ﬁll and freeze-dry the vaccine. In addition, we could
apidly reposition a pool of experts to oversee inﬂuenza vaccine
anufacture along with the necessary budgetary and management
upport to address technical, scientiﬁc and regulatory issues. On
he other hand, a disadvantage observed during interactions with
olicy-makers was the notion that the intentions of a commer-
ial enterprise are automatically biased. Signiﬁcant effort had to
e invested to prove this assumption wrong.S (2011) A16– A21
Regarding  production prospects, we  plan to produce at least
3–5 million doses of live attenuated seasonal trivalent vaccine and
examine the potential market for the combined North–South hemi-
sphere vaccine production with a view to manufacturing seasonal
inﬂuenza vaccine for the following year. Our installed capacity is
currently around 15 million doses of trivalent vaccine with the
potential for scale-up to nearly 30 million doses in 2011. We  have
enormous freeze-drying capacity, which means that we need to
focus only on considerations of bulk production.
However, in order to sustain the production of inﬂuenza vaccine
and to be able to address a pandemic situation, we need to maintain
a pool of qualiﬁed human resources who are up-to-date on the lat-
est developments in the ﬁeld of inﬂuenza, along with a small R&D
capacity to undertake virological experiments. The ability to handle
a pandemic threat also depends to some degree on the existence
of a routine inﬂuenza vaccination programme because this would
create the demand needed to make inﬂuenza vaccine manufactur-
ing ﬁnancially feasible. We  cannot rely on the Government of India
as a prospective buyer for this purpose since there are many health
priorities that precede the adoption of a seasonal inﬂuenza vac-
cination policy. On the other hand, with WHO  prequaliﬁcation, a
user-friendly delivery system and an affordable vaccine, we expect
to be able to offer LAIV to United Nations agencies for inclusion by
developing countries in their national immunization programme
(the WHO  technology transfer grant stipulates that at least 10% of
our pandemic inﬂuenza production must be made available to this
channel). In this way, we  hope to be able to sell sufﬁcient vaccine
to sustain our manufacturing activity.
Given that LAIV will be new to most countries, we also expect
the need for awareness-building over at least a year before the vac-
cine will be taken up. To this end, SII proposes to undertake further
studies on LAIV, for example to elucidate immunological corre-
lates of protection. To understand better the mechanisms of LAIV
protection with homologous as well as drifted strains, SII would
like to explore a human challenge trial using LAIV and carry out
well controlled experiments to collect more data on cell-mediated
immunity and other immunological parameters. However, this
research would require additional ﬁnancial and scientiﬁc support.
The  opportunity to work on inﬂuenza vaccine has opened up a
new era of South–South cooperation. For example, SII and the Gov-
ernment Pharmaceutical Organization (GPO) in Thailand have been
collaborating on the development of LAIV ever since seed strains
became available from IEM. Among other initiatives, the GPO team
visited SII to acquire the techniques and skills for their own  devel-
opment of LAIV. In a health crisis such as an inﬂuenza pandemic,
science should override commerce and SII is committed to such
collaborations.
7. Conclusion
The WHO  project to build capacity in developing countries to
manufacture pandemic inﬂuenza vaccine has provided India with
the critical skills needed to help protect its 1.2 billion popula-
tion from a deadly inﬂuenza pandemic. The technical inputs and
excellent coordination by the WHO  team were of immense help
in resolving several technical issues and enabling swift and pivotal
decision-making. Our ability to develop and market a pandemic
LAIV in such record time was  partly due to our long-standing
experience in vaccine manufacture, our qualiﬁed staff, and this
WHO collaboration. However, with hindsight, this would not have
happened without the exceptional ingenuity and commitment of
the SII team, who subdivided into independent virological, formu-
lation, analytical methods and clinical development groups, and
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In the future, LAIV and tissue culture may  be the way forward,
nd SII will continue its research and development efforts to remain
t the forefront of providers of solutions to major public health
riorities.
SII also intends to complete the work on development of candi-
ate H5N1 vaccine which we were compelled to discontinue in the
ake of H1N1 outbreak.
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